Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMKNRYH)

Drug Name

AKB-9778 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diabetic macular edema	9B71.02	Phase 2	[1]
Peripheral arterial disease	BD4Z	Phase 2	[2]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiopoietin 1 receptor (TEK)	TT9VGXW	TIE2_HUMAN	Activator	[1]
Protein tyrosine phosphatase beta (PTPRB)	TT64I9Q	PTPRB_HUMAN	Modulator	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Angiopoietin 1 receptor (TEK)	DTT	TEK	5.194	5.051	6.613	4.982

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Diabetic macular edema

ICD Disease Classification

9B71.02

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiopoietin 1 receptor (TEK)	DTT	TEK	4.92E-03	0.29	0.84

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02387788) Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO. U.S. National Institutes of Health.
3	Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201.